Zusätzlich zu Insulin – SGLT2-Hemmer erhält Zulassung für Typ-1-Diabetes
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Diabetes & Endocrinology
DEPICT-1-Studie mit Dapagliflozin: Mögliche Zusatztherapie
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Forxiga: Keine Zulassung mehr bei Typ-1-Diabetes | Apotheken Umschau
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials - The Lancet Diabetes & Endocrinology
Zulassungsempfehlung : Dapagliflozin als erste orale Add-on-Therapie bei Typ -1-Diabetes
BREAKING NEWS: First oral drug for type 1 diabetes set to be offered on the NHS as additional therapy to insulin - JDRF, the type 1 diabetes charity
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
A19-79 - Dapagliflozin - Addendum zum Auftrag A19-37 - Version 1.0
Sotagliflozin für Typ-1-Diabetes zugelassen
Dapagliflozin effective in treating type 1 diabetes
Dapagliflozin nicht mehr bei Typ-1-Diabetes anwenden
Dapagliflozin (Forxiga®) Zulassungsänderung | Gelbe Liste
Dapagliflozin darf nicht mehr bei Typ-1-Diabetes angewendet werden
Forxiga® 5 mg 28 St - shop-apotheke.com
Forxiga: Nicht mehr bei Diabetes Typ 1 | APOTHEKE ADHOC
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Zulassungsänderung - Keine Anwendung von Dapagliflozin bei Typ-1-Diabetes mellitus • diabetologie-online
